注:本文不构成任何投资意见和建议,以官方/公司公告为准;本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及)。
此前在2019年11月,EP Vantage发布报告,将BMS-986165列入生物制药领域最烧钱的TOP10新药研发项目。 ▲Kinase inhibition in autoimmunity and inflammation,nature reviews drug discovery
药融云数据 www.pharnexcloud.com;
http://www.chinadrugtrials.org.cn;
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast);https://investors.bms.com/iframes/press-releases/press-release-details/2021/Bristol-Myers-Squibb-Presents-Positive-Data-from-Two-Pivotal-Phase-3-Psoriasis-Studies-Demonstrating-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast/default.aspx; AAD 2021 Investor Presentation;https://s21.q4cdn.com/104148044/files/doc_presentations/2021/AAD-Investor-Presentation.pdf;
https://investors.bms.com/iframes/press-releases/press-release-details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study/default.aspx; Bristol
Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated
Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3
Psoriasis Study.,
https://www.businesswire.com/news/home/20201103005189/en; https://www.prnasia.com/story/297491-1.shtml;
https://www.bms.com/investors.html;
TYK2 inhibition shows promise,Nature Reviews Drug Discovery 18, 668 (2019),
doi: 10.1038/d41573-019-00134-4;
https://www.bms.com/researchers-and-partners/in-the-pipeline.html;
Most expensive clinical programmes – R&D projects;
JAK
inhibition as a therapeutic strategy for immune and inflammatory
diseases. Nature Reviews Drug Discovery,
https://doi-org.libproxy1.nus.edu.sg/10.1038/nrd.2017.201; Kinase inhibition in autoimmunity and inflammation,https://www-nature-com.libproxy1.nus.edu.sg/articles/s41573-020-0082-8,2020;等等。
各位朋友好,觉得本文对您有帮助,请随手点一下下方的在看,以便让你的朋友也能看到哦。